LOTTE (004990) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
15 Jan, 2026Executive summary
Consolidated 3Q25 revenue was KRW 4,154 billion, up 0.3% year-over-year, with operating profit rising 3.4% to KRW 185 billion, driven by global F&B growth and improved retail profitability.
Year-to-date (1-3Q25) revenue declined 1.7% to KRW 11,783 billion, and operating profit fell 16.5% to KRW 345 billion, reflecting ongoing restructuring and cost pressures.
Financial highlights
F&B division 3Q25 revenue grew 2.6% year-over-year to KRW 2,552 billion, with operating profit up 6.2% to KRW 178 billion, supported by global expansion and domestic efficiency.
Retail (Korea Seven) 3Q25 revenue dropped 8.4% year-over-year to KRW 1,273 billion, but operating losses narrowed due to store restructuring and improved per-store profitability.
Other businesses saw improved operating losses, notably from the liquidation of the healthcare business and transfer of the mobile gift certificate business.
Separate basis 3Q25 revenue and operating profit declined due to lower dividend and brand royalty income.
Outlook and guidance
Shareholder return policy targets a dividend payout ratio of 35% or more for 2024–2026, with a 2024 dividend per share of KRW 1,200 and a yield of 5.8%.
Management is focused on new growth themes: bio & wellness, mobility, sustainability, and new life platforms, with significant investment in biologics and digital platforms.
Latest events from LOTTE
- Targeting 35%+ shareholder return rate and growth via new businesses and ESG leadership.004990
Corporate Value-up Plan presentation15 Jan 2026 - 2Q25 saw lower revenue and profit, but 2H25 outlook is positive on expected consumption recovery.004990
Q2 202515 Jan 2026 - Record sales offset by profit decline from higher costs and affiliate losses; growth plans continue.004990
Q4 202415 Jan 2026 - Record revenue from F&B growth, but net profit negative amid equity losses and retail headwinds.004990
Q2 202415 Jan 2026 - Record revenue but net loss due to cost pressures; major biologics investments continue.004990
Q3 202415 Jan 2026 - Pursuing balanced growth via restructuring, global expansion, and new growth investments.004990
IR Day presentation15 Jan 2026 - Revenue and profit fell sharply, but global F&B and GRS growth offset weak domestic demand.004990
Q1 202515 Jan 2026